UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 22, 2014
PROVECTUS BIOPHARMACEUTICALS, INC.
(Exact name of registrant as specified in charter)
|
|
|
|
|
Delaware |
|
001-36457 |
|
90-0031917 |
(State or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(IRS Employer
Identification No.) |
7327 Oak Ridge Hwy., Knoxville, Tennessee 37931
(Address of Principal Executive Offices)
(866) 594-5999
(Registrants Telephone Number, Including Area Code)
(Former Name or Former Address, If Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 7.01. |
Regulation FD Disclosure. |
On September 22, 2014, Provectus Biopharmaceuticals,
Inc. (the Company) issued a press release announcing that the Company appointed Christopher Kaplan to its Strategic Advisory Board. A copy of the Companys press release is attached hereto as Exhibit 99.1 and is incorporated herein
by reference.
Pursuant to the rules and regulations of the Securities and Exchange Commission, the information in this Item 7.01
disclosure, including Exhibit 99.1 and information set forth therein, is deemed to have been furnished and shall not be deemed to be filed under the Securities Exchange Act of 1934.
Item 9.01. |
Financial Statements and Exhibits. |
(d) Exhibits.
|
|
|
Exhibit
Number |
|
Description |
|
|
99.1 |
|
Press Release, dated September 22, 2014 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Date: September 22, 2014
|
|
|
PROVECTUS BIOPHARMACEUTICALS, INC. |
|
|
By: |
|
/s/ Peter R. Culpepper |
|
|
Peter R. Culpepper |
|
|
Chief Financial Officer and Chief Operating Officer |
2
EXHIBIT INDEX
|
|
|
Exhibit Number |
|
Description |
|
|
99.1 |
|
Press Release, dated September 22, 2014 |
Exhibit 99.1
|
|
|
Contact:
Provectus Biopharmaceuticals, Inc.
Peter R. Culpepper, CFO, COO
Phone: 866-594-5999 #30 |
|
Porter, LeVay & Rose, Inc.
Marlon Nurse, DM, SVP Investor Relations
Phone: 212-564-4700
Bill Gordon Media Relations
Phone: 212-724-6312 |
PROVECTUS BIOPHARMACEUTICALS APPOINTS CHRISTOPHER KAPLAN TO ITS
STRATEGIC ADVISORY BOARD
KNOXVILLE,
TN, September 22, 2014Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT) (http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company (Provectus), announced today that it has
appointed Christopher Kaplan to its Strategic Advisory Board effective immediately.
Mr. Kaplan is currently President of Cajetan, LLC, an
independent healthcare consulting firm working with companies to deliver better value for patients, fuel innovation, enhance the impact and execution of marketing and sales initiatives, and reduce the cost and complexity of operating systems.
Prior to Cajetan, Mr. Kaplan spent two years with Boehringer Ingelheim as Senior Vice President and Chief Marketing Officer. That followed 12 years at
Novartis in both the US and Europe. Mr. Kaplan began at Novartis as Global Head Cardiovascular and Metabolic Business Franchise in Basel Switzerland, moved to Head Nordic Region Cluster and General Manager in Stockholm Sweden, then Head of
Northern and Central Europe and Region Europe Marketing & Sales back in Basel. He returned to the US as President, Cardiovascular & Metabolic Operating Unit, E. Hanover New Jersey, and then President and General Manager of the East
Operating Unit, also in E. Hanover.
Mr. Kaplan started his pharmaceutical career at Bristol-Myers Squibb Company. He moved quickly through various
roles in US sales and sales management and then in US marketing. He began his international experience in Paris as the CV Marketing Director for Europe and then progressed to his last role at Bristol-Myers Squibb as Marketing and Sales Director in
Rome, Italy.
Mr. Kaplan is a graduate of Columbia University, holds a Masters of Science Degree from the University of Pennsylvania, and undertook
post-graduate studies at INSEAD, Fontainebleu, France. He has also completed executive education programs at Harvard, Wharton and the London Business School.
Dr. Craig Dees, PhD, CEO of Provectus, said, Chris has a formidable resume and proven track record of success in pharmaceutical sales and
marketing. His experience in international business is clearly going to be an asset to Provectus, and I expect his dedication to healthcare innovation and delivery to be equally valuable.
Mr. Kaplan said, I am very pleased to be joining the Provectus Strategic Advisory Board at this
exciting time in the Companys development. I am impressed with the science that stands behind PV-10 as well as its prospects for regulatory approval.
About Provectus Biopharmaceuticals, Inc.
Provectus
Biopharmaceuticals, Inc., specializes in developing oncology and dermatology therapies. PV-10, its novel investigational drug for cancer, is designed for injection into solid tumors (intralesional administration), thereby reducing potential for
systemic side effects. Its oncology focus is on melanoma, breast cancer and cancers of the liver. The Company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. PH-10, its topical
investigational drug for dermatology, is undergoing clinical testing for psoriasis and atopic dermatitis. Provectus has completed phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a topical treatment for atopic dermatitis
and psoriasis. Information about these and the Companys other clinical trials can be found at the NIH registry, www.clinicaltrials.gov. For additional information about Provectus, please visit the Companys website at www.pvct.com or
contact Porter, LeVay & Rose, Inc.
FORWARD-LOOKING STATEMENTS: This release contains forward-looking statements as defined under
U.S. federal securities laws. These statements reflect managements current knowledge, assumptions, beliefs, estimates, and expectations and express managements current views of future performance, results, and trends and may be
identified by their use of terms such as anticipate, believe, could, estimate, expect, intend, may, plan, predict, project,
will, and other similar terms. Forward-looking statements are subject to a number of risks and uncertainties that could cause our actual results to materially differ from those described in the forward-looking statements. Readers should
not place undue reliance on forward-looking statements. Such statements are made as of the date hereof, and we undertake no obligation to update such statements after this date.
Risks and uncertainties that could cause our actual results to materially differ from those described in forward-looking statements include those discussed
in our filings with the Securities and Exchange Commission (including those described in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2013, and in our Quarterly Reports on Form 10-Q for the quarters ended
March 31, 2014, and June 30, 2014), and the following:
|
|
|
our determination, based on guidance from the FDA, whether to proceed with or without a partner with a phase 3 trial of PV-10 to treat locally advanced cutaneous melanoma and the costs associated with such a trial if it
is necessary; |
|
|
|
our determination whether to license PV-10, our melanoma drug product candidate, and other solid tumors such as liver cancer, if such licensure is appropriate considering the timing and structure of such a license, or
to commercialize PV-10 on our own to treat melanoma and other solid tumors such as liver cancer; |
|
|
|
our ability to license our dermatology drug product candidate, PH-10, on the basis of our phase 2 atopic dermatitis and psoriasis results, which are in the process of being further developed in conjunction with
mechanism of action studies; and |
|
|
|
our ability to raise additional capital if we determine to commercialize PV-10 and/or PH-10 on our own, although our expectation is to be acquired by a prospective pharmaceutical or biotech concern prior to
commercialization. |
###
Provectus Biopharmaceuti... (QB) (USOTC:PVCT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Provectus Biopharmaceuti... (QB) (USOTC:PVCT)
Historical Stock Chart
From Apr 2023 to Apr 2024